RankingsPricing
  1. US-listed companies
  2. Viridian Therapeutics, Inc.\DE
  3. Financials
  4. EBITDA margin (%)

Viridian Therapeutics, Inc.\DEVRDN

Market cap
$2.6B
P/E ratio
SummaryFinancials
Period EndEBITDA margin (%) YoY (%)
Dec 31, 2024-98,852.6+22.23%
Dec 31, 2023-80,875.8+969.46%
Dec 31, 2022-7,562.3+181.40%
Dec 31, 2021-2,687.4-74.39%
Dec 31, 2020-10,493.3+1023.13%
Dec 31, 2019-934.3+138.99%
Dec 31, 2018-390.9-40.34%
Dec 31, 2017-655.3+77.51%
Dec 31, 2016-369.2-14.85%
Dec 31, 2015-433.5+178.57%
Dec 31, 2014-155.6

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)